Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Actis Exits Chinese Diagnostics Business Chemclin For $150m
Private Equity

Actis Exits Chinese Diagnostics Business Chemclin For $150m

by dealstreetasia.com posted 9months ago 116 views
The firm invested in Chemclin in 2013 through a consortium led by Actis with China International Capital Corporation (CICC) Private Equity and OrbiMed to acquire a majority stake in the diagnostics company. The post Actis exits Chinese diagnostics business Chemclin for $150m appeared first on DealStreetAsia.

In this article